This is a profile image of Jeff Rudnicki

Jeff Rudnicki

Senior PartnerBoston

A leader in our global M&A strategy work who uses his experience to direct multiple client engagements, including more than 100 transactions across a broad range of industries

Jeff has helped clients with M&A work for more than 20 years. His engagements span the entire M&A process, from strategy and deal scan to due diligence and integration. Jeff also leads Synergy Lab, McKinsey’s synergy center of excellence, which helps clients apply best practices and data-driven insights to estimate synergies and capture value. He has a passion for working in the healthcare, technology, and consumer sectors, and for helping clients deepen their M&A capabilities to achieve lasting impact.

Examples of Jeff’s recent client work include the following:

  • building an M&A organization from scratch with a company that had grown inorganically, which allowed it to pursue a successful multibillion-dollar transaction
  • working closely with the CEO and board of a multibillion-dollar medical-device company to shape an M&A strategy and conduct due diligence for an industry-shaping acquisition
  • leading the project management, organizational-design, and talent teams during the integration of a global rare-disease transaction that included several strategic divestments and transformed the performance and focus of the company
  • assisting in driving the integration of two luxury brands, which more than quadrupled initial synergy estimates
  • designing a new investor-relations model that changed the way organizations prioritized investors, deployed executives, and allowed for a streamlining of the quarterly earnings process
  • advising the CEO and board of an academic medical center on its strategy for consolidating systems to build scale and strengthen capabilities as it became a leader in value-based care
  • building a new IPO strategy for a leading sports-equipment company

Prior to joining McKinsey, Jeff spent eight years as an antitrust economist, specializing in the regulatory implications of M&A. He previously served as Vice Chair for the board of the March of Dimes in Boston and Manchester.

Published Work

Life sciences M&A shows new signs of life,” McKinsey & Company, February 2024

What programmatic acquirers do differently,” McKinsey & Company, February 2024

The flip side of large M&A deals,” McKinsey & Company, March 2022

Practice makes perfect: What sets programmatic acquirers apart,” McKinsey & Company, November 2019

How lots of small M&A deals add up to big value,” McKinsey Quarterly, July 2019

Get more procurement value from M&A—even before closing,” McKinsey & Company, July 2018

The artful synergist, or how to get more value from mergers and acquisitions,” McKinsey & Company, February 2017


UVA Darden School of Business

Johns Hopkins University
MA, economics

Pennsylvania State University
BS, economics